OTCMKTS:ICOTF iCo Therapeutics (ICOTF) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free ICOTF Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.34▼$0.3450-Day Range$0.30▼$0.4252-Week Range$0.80▼$1.82VolumeN/AAverage Volume4,760 shsMarket Capitalization$3.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get iCo Therapeutics alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About iCo Therapeutics Stock (OTCMKTS:ICOTF)Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.Read More Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> ICOTF Stock News HeadlinesMay 10, 2023 | wsj.comICO Group Ltd.February 25, 2023 | marketwatch.comAntisense & RNAi Therapeutics Market 2023 Estimated to Perceive Exponential Growth till 2028April 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.February 19, 2023 | finance.yahoo.comWomen's health therapeutics market size to increase by USD 30.35 billion: North America to account for 37% of market growth - TechnavioFebruary 19, 2023 | seekingalpha.comJasper Therapeutics releases promising early-stage data on sickle cell disease treatmentOctober 10, 2022 | usnews.comConsumers to Ditch Cafes for Coffee at Home Amid Rising Prices, Says ICOAugust 16, 2022 | investing.comSatellos Bioscience Inc (MSCL)June 1, 2022 | seekingalpha.comSatellos Bioscience GAAP EPS of -C$0.06April 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.December 16, 2021 | finance.yahoo.comSatellos Bioscience Inc. Announces Scientific Research Agreement with Université de Sherbrooke to Study Rare Muscular DystrophiesDecember 15, 2021 | finance.yahoo.comSatellos Bioscience to Webcast Live at Life Sciences Investor Forum December 16thDecember 9, 2021 | finance.yahoo.comICOTF: Targeting Stem Cells for Muscular Dystrophy TreatmentDecember 6, 2021 | finance.yahoo.comSatellos Bioscience Announces New Board AppointmentsDecember 2, 2021 | investing.comiCo Therapeutics Inc (MSCL)November 29, 2021 | finance.yahoo.comSatellos Bioscience Reports Third Quarter 2021 Financial Results and Operational HighlightsOctober 27, 2021 | finance.yahoo.comSatellos Bioscience Inc. Retains BND Projects Inc. for Strategic Investor Relations ServicesAugust 5, 2021 | finance.yahoo.comiCo Therapeutics Inc. Announces Shareholder Approval of Business Combination with Satellos Bioscience Inc.See More Headlines Receive ICOTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iCo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:ICOTF CUSIPN/A CIKN/A Webwww.icotherapeutics.com Phone(905) 336-6128Fax604-602-9699EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,110,000.00 Net MarginsN/A Pretax Margin-4,148.78% Return on EquityN/A Return on Assets-288.85% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-4.87Miscellaneous Outstanding Shares9,054,000Free FloatN/AMarket Cap$3.08 million OptionableNot Optionable Beta2.03 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesFrank GleesonPresident & Chief Executive OfficerWarren WhiteheadChief Financial OfficerMichael RudnickiChief Scientific OfficerJ. Robert HallVice President-Finance & AdministrationKey CompetitorsPhio PharmaceuticalsNASDAQ:PHIOAridis PharmaceuticalsNASDAQ:ARDSCyclacel PharmaceuticalsNASDAQ:CYCCAraviveNASDAQ:ARAVMateon TherapeuticsOTCMKTS:MATNView All Competitors This page (OTCMKTS:ICOTF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry ResearchForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iCo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
